Metacrine Inc
MTCR
Get informed when a big investor buys or sells
+ FollowMarket Cap$0
Close$
Share Statistics
| Market cap | $0.00 |
|---|---|
| Enterprise Value | $-38,964,000.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.45 |
| Beta | -0.74 |
| Outstanding Shares | 42,569,515 |
Return
| Return on Equity | -106.08% |
|---|---|
| Return on Assets | -71.44% |
| Return on Invested Capital | -72.28% |
Valuation & Multiples
| P/E Ratio | -0.4 |
|---|---|
| PEG | 0.56 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 1.07 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.35 |
| Debt to Equity | 0.37 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Metacrine Inc
35 employeesMetacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies to treat liver and gastrointestinal diseases. Metacrine has developed a proprietary farnesoid X receptor (FXR) platform utilizi...